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Abstract: HIV-1 genetic diversity can be used to infer time since infection (TSI) and infection recency.
We adapted this approach for HCV and identified genomic regions with informative diversity.
We included 72 HCV/HIV-1 coinfected participants of the Swiss HIV Cohort Study, for whom reliable
estimates of infection date and viral sequences were available. Average pairwise diversity (APD)
was calculated over each codon position for the entire open reading frame of HCV. Utilizing cross
validation, we evaluated the correlation of APD with TSI, and its ability to infer TSI via a linear model.
We additionally studied the ability of diversity to classify infections as recent (infected for <1 year) or
chronic, using receiver-operator-characteristic area under the curve (ROC-AUC) in 50 patients whose
infection could be unambiguously classified as either recent or chronic. Measuring HCV diversity
over third or all codon positions gave similar performances, and notable improvement over first or
second codon positions. APD calculated over the entire genome enabled classification of infection
recency (ROC-AUC = 0.76). Additionally, APD correlated with TSI (R2 = 0.33) and could predict
TSI (mean absolute error = 1.67 years). Restricting the region over which APD was calculated to
E2-NS2 further improved accuracy (ROC-AUC = 0.85, R2 = 0.54, mean absolute error = 1.38 years).
Genetic diversity in HCV correlates with TSI and is a proxy for infection recency and TSI, even several
years post-infection.
Viruses 2020, 12, 1241; doi:10.3390/v12111241 www.mdpi.com/journal/viruses
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1. Introduction
Inferring the duration of infection is of key importance for understanding both the epidemiology
and pathogenesis of hepatitis C virus (HCV) infections. From an epidemiological perspective, the time
of infection can inform incidence assays, phylogenetic studies, and prediction of future chronic liver
disease burdens. In particular, it could be vital for monitoring public health progress in the context of
elimination [1], as it enables the identification of ongoing transmission. From an individual-patient
perspective, this information could contribute to knowledge of disease progression and assessment.
The nature of HCV transmission and its mostly asymptomatic acute infection means that the
date of infection is rarely known, and there is a lack of known biomarkers available from which this
information could be estimated. Accordingly, studies typically have to rely on some combination of
cohort data and mathematical modelling to infer infection dates [2–13], which remain highly uncertain
for most HCV-infected individuals. In the present study, we took advantage of the unique opportunity
of a cohort with annual HCV screening, detailed clinical characteristics, and sampling.
A similar problem exists for human immunodeficiency virus-1 (HIV-1), which is also an RNA
virus of comparable genome size that chronically infects patients. For HIV-1, it has been shown that
viral diversity can be used to infer infection recency [14–16] and time since infection [17], and that
diversity derived from next-generation sequencing (NGS) sequences is more accurate than diversity
derived as the fraction of ambiguous nucleotides from Sanger sequences [18].
In this study, we aimed to investigate whether the same NGS-derived-diversity method can
be applied to HCV, and to identify the region of the genome over which it is most informative to
measure diversity.
2. Materials and Methods
2.1. Patients
We included 72 HCV-HIV coinfected patients from the Swiss HIV Cohort Study (SHCS), for
all of whom an NGS-sequenced HCV sample was available. For patients enrolled in the SHCS,
HCV-serologies are determined since 2000 every 12–24 months. Therefore, the patients considered
in our study had a date of HCV infection known to within 24 months. This date of infection was
calculated as the midpoint between the date of the most recent negative (RNA or antibody) test prior
to the sample date, and the earliest date of either a positive HCV (RNA or antibody) test result, or the
date at which the sample was taken. Patient characteristics are summarized in Table 1.
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Table 1. Patient characteristics.
Total Number 72
Gender, n (%) Female 2 (3)
Male 70 (97)
Age when sample taken (years), median (IQR) 45 (39, 52)
Ethnicity, n (%)
Asian 2 (3)
Black 2 (3)
Hispanic 4 (4)
White 64 (89)
HIV transmission group, n (%)
HET 3 (4)
MSM 67 (93)
IDU 1 (1)
Unclear/unknown 1 (1)
Recorded history of intravenous drug use ever, n (%) Yes 9 (13)
No 63 (88)
HCV Viral subtype, n (%)
1A 50 (69)
1B 5 (7)
2C 1 (1)
3A 2 (3)
4D 14 (19)
Time since HCV infection (years), median (IQR) 0.82 (0.47, 2.5)
Clearly recent or chronic a, n (%) True 50 (69)
False 22 (31)
Full coverage of gene at all codon positions, n (%)
C 69 (96)
E1 69 (96)
E2 70 (97)
p7 70 (97)
NS2 70 (97)
NS3 71 (99)
NS4A 71 (99)
NS4B 70 (97)
NS5A 69 (96)
NS5B 65 (90)
IQR = Interquartile range, HET = heterosexual contacts, MSM = men who have sex with men, IDU = injection drug
use. a Sample collection less than 12 months after last negative HCV test or more than 12 months after first positive
HCV test.
2.2. Sequencing
Samples were sequenced in the context of two different projects, resulting in differing, although
similar, protocols. Briefly, the following sequencing protocols were used:
Project 1, as part of the Swiss-HCVree-trial (NCT02785666) [19] within the SHCS, 53 samples (see
Supplementary Material S1 for the description of near full-length genome sequencing): cDNA was
synthesized and amplified using a one-step reverse transcription and PCR kit, or in two individual
steps. Some samples then underwent a second, nested-PCR (Supplementary Table S1). Samples
were pooled for sequencing, and libraries were run using MiSeq (Illumina, San Diego, CA, USA) 1 ×
150 cycles.
Project 2, within the SHCS, 19 samples: Viral RNA was extracted from plasma stored in the
SHCS biobank by the Nucleospin RNA Virus Kit (Macherey-Nagel, Düren, Germany). RNA was then
amplified by RT-PCR in a two-step process, and some samples underwent a second, nested-PCR if
necessary. HCV RNA genome sequences were generated by amplification of almost full-length HCV
RNA followed by massive parallel sequencing. A MiSeq (Illumina, San Diego, CA, USA) instrument
was used for sequencing with 2 × 250 bp.
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Sequences were processed using MinVar version 2.2.1 (https://github.com/medvir/MinVar) [20],
which filters and aligns reads before returning sequence variants. A slightly modified script was used
in order to output sequence position information at the nucleotide level.
2.3. Diversity Score Calculation
Average pairwise diversity (APD) was calculated from nucleotide minority variant frequencies
using Equation (1) [17], explanation as in [18]. This first determines whether a position has minor
variants above a threshold, and subsequently sums the diversity contribution of all variants at that
position. Finally, diversity across all positions is averaged. This value is functionally equivalent to the
average proportion of positions at which two randomly selected sequences differ.
APD =
1
L
L∑
i=1
Θ
(
1− xmi − xc
)∑
α
xiα(1− xiα)
 (1)
where
L = length of analysed sequence.
i = sequence position.
xim = frequency of major variant m at position i.
xc = 0.01.
Θ(x) =
{
1, x > xc
0, x ≤ xc
α ∈ {A,C,G,T,deletion}.
xiα = frequency of variant α at position i.
xc is a frequency cut-off, below which variants are considered to be indistinguishable from those
generated by PCR or sequencing errors. It was set to 1% as this is the approximate detection limit of a
high-throughput sequencing workflow (Illumina) [21,22].
We calculated average pairwise diversity over various subsections of the HCV genome open
reading frame:
− All codon positions, and only the first/second/third codon positions in turn.
−Whole open reading frame, individual genes, and 11 overlapping equal regions that the genome was
split into (length = 502 or 501 amino acid codons).
2.4. Data Analysis
All results were analysed in R version 3.5.1 [23], using packages data.table [24], pROC [25],
readstata13 [26], and RColorBrewer [27].
We examined how well average pairwise diversity correlated with time since infection (TSI)
using linear regression. This linear model (Equation (2)) was then validated using leave-one-out
cross-validation, with mean absolute error as the primary outcome. This was conducted by calculating
the model coefficients using all but one sample, and then applying this model to the remaining "test"
sample. The absolute value of the difference between the estimated and actual time since infection was
then calculated for this test sample. This procedure was repeated for all samples in turn, and the mean
value of all the absolute errors was taken, providing a simple measure by which to compare average
pairwise diversity calculated across different regions.
Estimated TSI = β APD + α (2)
We studied how well average pairwise diversity could be used to infer infection recency using
receiver operator characteristics (ROC) analyses, with recent infection (<1 year post-infection) defined
as the positive outcome. We restricted these recency analyses to the 50 patients who could be
unambiguously classified as recent (21 patients) or chronic (29 patients) due to the sample having been
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collected less than 12 months after the last negative HCV test or more than 12 months after the first
positive HCV test.
A sensitivity analysis was conducted to assess variability between viral subtypes, as levels of
diversity have been seen to vary between subtypes [28]. We therefore repeated our analyses using just
those patients infected with subtype 1A, and 4D; insufficient number of samples were available from
other viral subtypes for this analysis to be meaningful for them.
2.5. Ethics Approval and Consent to Participate
This analysis was conducted in the context of the SHCS which was approved by the ethics
committees of the participating institutions (http://www.shcs.ch/userfiles/file/ethics_committee_
approval_and_informed_consent.pdf, Kantonale Ethikkommission Bern, Ethikkommission des
Kantons St. Gallen, Comité Départemental d’Éthique des Spécialités Médicales et de Médicine
Communataire et de Premier Recours, Kantonale Ethikkommission Zürich, Repubblica et Cantone
Ticino–Comitato Ethico Cantonale, Commission Cantonale d’Éthique de la Recherche sur l’Être Humain,
Ethikkommission beider Basel), and written informed consent was obtained from all participants. The
study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki.
3. Results
3.1. Codon Position Makes a Notable Difference in Average Pairwise Diversity Scores
We found for the first and second codon positions a substantial correlation with time since infection
but also that diversity remains low even several years post-infection (Figure 1). Conversely, average
pairwise diversity over the third codon position shows a large and steady increase with time since
infection, and should therefore be more informative when inferring time since infection and infection
recency. However, calculating average pairwise diversity over all three positions yields similar results
to considering only third-codon positions (Figure 1). This suggests that average pairwise diversity
calculated over either third or all codon positions may be capable of inferring time since infection with
reasonable precision.
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Figure 1. Average pairwise diversity (APD) against time since infection for APD calculated over each
of the codon positions in turn, and over all three codon positions. Linear regression models are shown
as solid lines.
We compared how well average pairwise diversity over individual and all codon positions could
infer infection recency using ROC analyses (Figure 2). This analysis, was restricted to the 50 patients
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whose infections could be unambiguously classified as either recent (time since infection <1 year)
or chronic (time since infection >1 year). In line with Figure 1, using third and all codon positions
outperforms using first and second codon positions, supporting the notion that average pairwise
diversity calculated over these positions is more informative. Due to the similarity between using
the third codon and all codon positions, we continued our analyses using average pairwise diversity
calculated over all codon positions, this being the easier measure to calculate as it does not require
identification of the reading frame (results over the third codon position are provided in Supplementary
Figure S1 for comparison and give very similar outcomes).
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Figure 2. Receiver operator characteristics (ROC) curves comparing the ability of average pairwise
diversity (APD) calculated over each and all codon positions to infer whether infections are recent (<1
year post-infection) or chronic. APD was calculated across the whole HCV open reading frame. All 50
patients who could be clearly classified as recent or chronic are included. Recent infection is taken as
the positive outcome. AUC = area under the ROC curve.
3.2. Restricting Average Pairwise Diversity to Certain Regions of the Genome Improves Inference of Time since
Infection and I fection Recency
We calculated average pairwise diversity over the entire open reading frame of HCV, each gene
individually, and for regions derived by i iding the open reading fram into eleven equal overl pping
regions. We then assessed h w well each average pairwise diversity scores could be used to infer
infection recency (via ROC analyses) and time since inf ction ( ia linear regression and cross-validation).
When comparing the thre outcomes (area under the ROC curve, R2, and mean bsolute rror) f r all
regi ns across the open reading frame (Figure 3), we find th t the region covering amino acid codons
503-1004– provides the best score for all thr e outcomes. This region spans the major 3′ part of E2, the
entirety of p7, a d the majority of the NS2 genes. The regions covering the last 1000 amino acid codons
of the open re ding frame also perform well, but less consistently acr ss outcomes (Figure 3). The
figure also shows the HCV ge es colour-coded by a composite score of all three outcomes, from which
a similar pattern emerges, with E2 and NS2 individually performing especially well. We therefore
additionally calculated averag pairwis diversity over the three genes E2, p7 and NS2 combined and
found similarly st ong result . Supplem ntary Table S2 provi es the exa t scores for all th regions
tested. Supplementary Figure S2 hows the same analysis rep ated for larger regions, which provides
a similar outcome.
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as recent (<1 y ar) or chronic (top), their correlation with time since infection (middle), a d their ability
to infer time since infection (bottom). Black dashed lines show the respective valu s for APD calculated
over the whol open reading fram . A simila analysis was performed with diversity calculated
over each gene in turn. The HCV genome is shown along the x-axis, with genes colour-coded for
a composite (z-score sum, see Supplementary Equation S1) of all three outcome scores. Darker red
indicates a better ov rall p rfo mance. Numbers along the x-axis refer to amino acid positions of the
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Based on these results, we recom end calculating average pairwise diversity using all codon
positions, over the region of amino acid codons 503-1004– of the open reading frame, or using the
entirety of genes E2, p7 and NS2 together. Time since infection can be estimated from these scores
using Equation (2), with recom ended coefficients alpha = 0.42, beta = 353.70 for average pairwise
diversity over the region 503-1004–, or alpha = 0.39, beta = 320.38 for average pairwise diversity over
E2, p7 and NS2. A full list of suggested coefficients for all regions tested is available in Sup lementary
Table S2. Figure 4 shows the time since infection against estimated time since infection for the
recommended regions.
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and the recommended genes E2, p7, and NS2 (right).
3.3. Sensitivity Analysis Shows Minor Variation between Viral Subtypes
We conducted a sub-analysis including only patients infected with viral subtype 1A (50 patients,
of which 33 could be included in the ROC analysis), and 4D (14 patients, of which 10 could be included
in the ROC analysis), using average pairwise diversity calculated over our recommended regi ns. For
diversity calculated over amino acid codons 503–1004, the area under the ROC curve was the same as
the verall score of 0.85 for genotyp 1A (0.85) and slightly lower for genotype 4D (0.67). Conversely,
R2 was slightly higher than the overall score of 0.48 for genotype 4D (0.56), and lower for genotype 1A
(0.43), whilst mean absolute error was worse than th overall 1.44 years for both genotype 1A (1.64
years) and 4D (1.52 years). A similar pattern was seen for average pairwise diversity over the genes E2,
p7, and NS2 (overall: area under the ROC curve = 0.85, R2 = 0.54, mean absolute error = 1.38 years. 1A:
area under the ROC curve = 0.86, R2 = 0.51, mean absol te error = 1.51 years. 4D: area under the ROC
curve = 0.62, R2 = 0.56, mean absolute error = 1.46 years).
4. Discussion
Overall, this study shows that HCV genetic diversity as calculated from nucleotide frequencies
derived from NGS deep sequencing correlates with, and c n be used to infer, the time sinc infect on
and infection recency. A wide ra ge of samples of well-defined infect on timepoints with differing
i fection durations was included, showing that this method could b employed for samples up to 16
years post-infection. With a mean absolute error of less an 1.5 years, this method can provide insight
which may b particularly helpful for p blic health monitoring in the context of HCV elimination
strategies, and the identification of rec nt versus chronic infections.
We additionally co uct d analyses f cusing o individual reg ons a ross the entire open reading
frame, and have shown that th p ttern of diver ty differs across the genome, with some regions and
co o s experiencing differing levels of diversification over time. The contrast in diversity calculated
over codons 1 or 2 compar d to co on 3 hi hlights the strong effect of s lection against non-synonymous
mutations. It should be n ted, however, hat even at third-codon positions substitutions will not be
c mpletely neutral, as they can for example affect RNA secondary structure. Even though such effects
may restrict the accumulation of viral diversity, they do not seem to have had a major effect on the
association between time since infe ion and divers ty as indicated by similarly str ng correlations
observed ver the e tire HCV gen me (Figure 3). For example, we observed one of the strongest
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associations for the NS5B gene, which (in its second half) exhibits a particularly high density of regions
encoding for RNA secondary structure [29,30]. Surprisingly, the most informative region was found to
include the E2 gene. As this encodes one of the two viral envelope proteins, a generally high level
of diversification is unsurprising, but it was expected that selective sweeps due to immune system
pressure would result in an unsteady increase in diversity unsuitable for inferring time since infection,
as has been seen for the HIV envelope gene [17]. This finding defies that and suggests that other factors
may be additionally influencing the accumulation of diversity within the HCV genome, causing a
steadier increase.
As some variation between diversity within different viral subtypes has been reported [28], we
conducted a sensitivity analysis with individual subtypes to evaluate the impact of viral subtype
on our analyses. Whilst some variation was observed, overall patterns were robust across subtypes
Furthermore, the largest deviation from the overall results was found for the subtype 4D ROC analyses
which were conducted with only 10 samples. Our results, hence suggest that this method is applicable
across different viral subtypes; however, further analysis with more samples of different subtypes is
required to confirm this.
This study was limited by the number of samples available, which were all from patients already
infected with HIV-1 at the time of HCV sampling, and primarily from men who have sex with men
(MSM) with no recorded history of intravenous drug use (60/72 patients). The small sample size
(and especially the small number of patients with large infection times) prevented the examination of
non-linear effects, such as a potential saturation of diversity at large infection times, which has been
observed for HIV-1 [14,18]. Furthermore, the presence of HIV-1 may affect the diversification of HCV
over time, given the known impact of HIV-1 infection on HCV infection [31–33], and the increased
virus load of HCV in the presence of HIV-1 [34–36]. The HCV epidemic typically consists primarily
of people who inject drugs, but there is growing incidence of HCV infections among HIV-infected
MSM [11,12,37–41]. As our study population consists almost exclusively of MSM, the validity of our
results in people who inject drugs needs to be examined in future studies. Furthermore, our samples
were derived from two different projects and therefore prepared and sequenced by slightly differing
protocols. Whilst this variation in preparation and sequencing methods may remove some uniformity
from our sample set, it more accurately reflects the scenario should the method be applied to HCV
samples that have been collected and sequenced for a variety of purposes and can therefore be seen as
a strength of this study.
As drug resistance testing is not routinely performed for HCV-infected patients, the availability of
NGS sequences for this technique may be limited. However, as the price of NGS sequencing methods
is decreasing, they are likely to be increasingly employed for surveillance purposes and gaining
epidemiological understanding. Particularly in the context of elimination strategies, sequence-based
information such as viral phylogenies and origins may be very desirable. Our study found a substantial
correlation between time since infection and average pairwise diversity. Based on this, we could show
that infection recency and time since infection can be accurately predicted by using average pairwise
diversity. Thus, in the cases where samples from HCV-infected persons are sequenced, this method
provides recency and date of infection information as free by-products of standard NGS sequencing,
which can add to such monitoring studies.
Supplementary Materials: The following are available online at http://www.mdpi.com/1999-4915/12/11/1241/s1.
Supplementary material S1: Full protocol for preparation and sequencing of samples for study 1; Table S1:
Summary of preparations methods for sequencing for study 1; Table S2: Scores for average pairwise diversity
calculated over all codon positions, and over various regions of the open reading frame, with associated coefficients
from linear regression (AUC = area under the ROC curve, adj. R2 = adjusted R2, MAE = mean absolute error);
Figure S1: Area under the ROC curve, R2, and mean absolute error across the HCV open reading frame, third
codon positions. The HCV open reading frame was split into 11 overlapping regions of approximately 500 amino
acid codons, and average pairwise diversity (APD) was calculated over individual regions, using the third codon
positions. Regions were tested for their ability to categorise infection as recent (<1 year) or chronic (top), their
correlation with time since infection (middle), and their ability to infer time since infection (bottom). Black dashed
lines show the respective values for APD calculated over the whole open reading frame. A similar analysis was
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performed with diversity calculated over each gene in turn. The HCV genome is shown along the x-axis, with
genes colour-coded for a composite (z-score sum) of all three outcome scores. Darker red indicates a better overall
performance. Numbers along the x-axis refer to amino acid positions of the H77 reference genome; Figure S2:
Area under the ROC curve, R2, and mean absolute error across the HCV open reading frame, all codon positions.
The HCV open reading frame was split into 5 overlapping regions of approximately 1000 amino acid codons, and
average pairwise diversity (APD) was calculated over individual regions, using all codon positions. Regions were
tested for their ability to categorise infection as recent (<1 year) or chronic (top), their correlation with time since
infection (middle), and their ability to infer time since infection (bottom). Black dashed lines show the respective
values for APD calculated over the whole open reading frame. A similar analysis was performed with diversity
calculated over each gene in turn. The HCV genome is shown along the x-axis, with genes colour-coded for a
composite (z-score sum) of all three outcome scores. Darker red indicates a better overall performance. Numbers
along the x-axis refer to amino acid positions of the H77 reference genome; Equation S1: Z-score for converting
outcome scores to be summed into a combined single score.
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